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Fertility regulation during human lactation
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Introduction
Although steroid contraceptives have been in widespread use for many years, there
still appears to be considerable uncertainty in the minds of many clinicians and
family planning programme decision-makers regarding their prescription to
nursing mothers. This uncertainty appears to be reflected in replies to a question-
naire sent by the Human Reproduction unit of WHO to scientists in its network of
Collaborating Centres for Clinical Research in Human Reproduction regarding the
current status of the use of steroid contraceptives by nursing mothers in different
national settings. Although the information was, of necessity, in some cases
imprecise, the following impressions were gained about eighteen countries:
(Australia, Canada, Chile, Egypt, Holland, Hungary, India, Mexico, Nigeria,
Philippines, Singapore, Sri Lanka, Sweden, Thailand, Turkey, United Kingdom,
USA, Zambia).
Government policies seem to vary from unqualified or qualified approval
or recommendation to disapproval, and not surprisingly the practice in sectors
other than governmental tends to be influenced by the given policy. In the absence
of specific government policy, a situation apparently applying in approximately
half of these countries, the decision seems to be left to the discretion of individual
practitioners. Existing policies or practices are by no means uniform and vary in
respect of different preparations, their availability and the timing of first admini-
stration after delivery, and the importance placed on breast-feeding, which in
developing countries is almost the only way to ensure adequate nutrition of the
infant. Such are the variables involved, including patient preference for a given
method, it is difficult to estimate on a global scale the extent to which steroid
contraceptives are prescribed to nursing mothers, and more information is
needed on this point.
It is now generally accepted that the post-partum phase represents one parti-
cular phase when women may most readily be motivated to accept family planning
advice. Some will accept an IUD, others will prefer a traditional method, and
others will prefer a steroid contraceptive and be reluctant to use any other method.
It has been postulated that the recommendation, based upon potentially
adverse effects, to withhold steroid contraceptive prescription until lactation is
fully established or until 3 or more months post-partum, has led to the loss of many
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potential acceptors, because, following the break in continuity of care these women
frequently fail to return. Whilst this may be the case, if a nursing mother using
steroid contraception has any suppression of lactation it may lead to impaired
infant growth and increased risk of morbidity associated with early supplementary
feeding. To remedy matters she may decide to discontinue its use, but will then
expose herself to the risk of further conception unless she uses an alternative
form of reliable contraception. On the other hand, if her main concern is to avoid
conception she may elect to continue with its use at the expense of lactation and
wean her infant prematurely, unaware of the risks associated with unhygienic or
inadequate artificial feeding.
There is still insufficient scientific knowledge upon which to draw definitive
and universally applicable conclusions concerning which steroid contraceptives
may be safely prescribed to breast-feeding mothers, and in what dosage and how
soon after delivery. There are two fundamental questions which have not been
resolved to date with absolute certainty. First, do contraceptive steroids indivi-
dually or in combination have any adverse effect on lactational performance,
measured by the quantity and quality of milk supply and the duration of lactation?
Second, to what extent if any are these steroids in biologically active form trans-
ferred via the milk to the infant, and what is the significance of such transfer?
The need for further research to clarify uncertainty regarding these issues has
been repeatedly identified during the last few years (Chopra, 1972; IPPF, 1976;
Buchanan, 1975; Thomson, Hytten & Black, 1975; WHO, 1975). Dissemination
of the knowledge gained would not only enable physicians to advise their nursing
patients with confidence on the effects of steroid contraceptives if used during
lactation, but should provide clear guidance to decision makers in the development
of post-partum strategies in their family planning programmes.
The World Health Organization is making efforts to respond to this recognized
need through its Expanded Programme of Research, Development and Research
Training in Human Reproduction.
Influence of steroid contraceptives on lactational performance
A study of the published research to date reveals the problems which faced
those who have attempted to draw conclusions from reviews of the pertinent
literature (Chopra, 1972: Buchanan, 1975; Thomson et al., 1975; Vorherr, 1973).
In summary, it may be said that the interpretation of the results from the many
studies undertaken is difficult for many reasons—variations in the type and dose of
preparations used, in the timing of first administration, and in the frequency and
duration of observations; variations in the methodology used to measure lactational
performance, e.g. maternal subjective impressions and retrospective estimates of
the duration of lactation, even including that following previous pregnancies, have
been used in some studies; variations in, or absence of information on, the precise
methodology used to quantify milk volume; and many studies do not appear to
have taken into consideration such variables as infant birth weight and maturity,
infant or maternal morbidity, parity and maternal age. In many studies control
subjects have been omitted and in comparing the effect of different pills the use of a
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double-blind packaging approach, which many would consider essential, is not
specifically mentioned.
Thus it becomes difficult to draw conclusions. Nevertheless, despite these
reservations it seems clear that certain generalizations can be made. The majority of
published studies imply that combination pills containing high doses of oestrogen,
and even in certain studies implicating those containing 50 fig, adversely affect
lactational performance, but to what extent this effect is significant is very open to
question. Indeed in a recent editorial article in the Lancet (Anon, 1976), attention
is drawn to the conclusion of Thomson et al. (1975), following their wide review,
that where efficient contraception is required, low-dose oestrogen-containing oral
preparations present no serious threat to continued breast-feeding. The effects
most frequently reported, measured either subjectively or objectively, are a de-
crease in milk volume requiring early or additional supplementation, and a de-
crease in the duration of lactation in some cases with premature cessation.
No studies are as yet known to have been published on the use of new low-dose
oestrogen combination pills, i.e. those containing 30 fig of oestrogen, towards the
use of which there appears to be a trend in some countries.
On the other hand, the majority of studies concerned with the use of pro-
gestogen only oral preparations have shown no detrimental effect on lactation, nor
have those investigating the use of injectable preparations, which have been re-
ported by some investigators even to enhance lactation.
The evidence from those studies which sought to determine the effect of
combination or progestogen-only oral steroid contraceptives and injectable
preparations on the composition of human milk is conflicting and difficult to
interpret—perhaps due to the variations in the preparations studied, the timing
of their administration, the duration of observations, and in assay techniques.
Studies in this whole field are acknowledged to be difficult to conduct, but
against this overall background of doubt and uncertainty arising from multiple
individual studies one approach appears necessary—the conduct of a collaborative
study in several centres from both developed and developing countries to compare
prospectively the effects of a limited number of different steroid preparations on the
lactational performance of nursing mothers.
Such a study entails the elimination of as many variables as possible by, e.g.
(1) pre-treatment observations at fixed times post-partum, (2) the commencement
of contraceptive therapy at a fixed time post-partum in the study groups, (3) the
use of control groups, e.g. those who elect to take no contraceptive measures and
who are not concerned whether they become pregnant or not, and those who elect
to use a non-medicated IUD, (4) matching as far as possible subjects between
groups for maternal age, socio-economic class, parity, infant birth weight and
maturity, within specified ranges, (5) adopting a standardized approach to the
collection of milk to assess output at prescribed intervals over a prescribed period
of time, and (6) the use of standard milk sampling and assay techniques for the
assessment of composition.
Since there is a suggestion that even those combination pills containing only
50 fig of oestrogen may have an adverse effect on lactation, however inconclusive
the evidence, it would now seem more prudent to compare the effects of an oestro-
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gen combination pill containing only 30 /xg oestrogen with that of a pill containing
only the same type of progestogen used in the combination formula, e.g.
d-norgestrel + ethinyl oestradiol versus d-norgestrel only. Such pills should be pre-
pared with an identical appearance and packaged to ensure double-blind com-
parison. Although obviously it would be impossible to compare in addition the
effects of injectables on a double-blind comparative basis the inclusion of groups
given either DMPA or NET-oenanthate would be highly desirable.
Careful monitoring of both infant and maternal progress would be mandatory.
If such a project, a protocol relating to which is at present in the final stages of
review within WHO, could be implemented successfully, it should provide much of
the information needed for the solution of the first question.
Transfer of contraceptive steroid hormones/metabolites and their fate/
significance as far as the infant is concerned
If steroid contraceptives are prescribed post-partum to nursing mothers, it is
conceivable that their offspring whose detoxicating mechanisms may not be fully
developed would be exposed to these steroids or their active metabolites if they
were to appear in the maternal milk.
No studies have yet been performed which clearly demonstrate the significance
of any such possible transfer via human milk as far as the infant is concerned,
especially if steroids are prescribed to these mothers over prolonged periods.
Vorherr (1973) in his review of current developments in contraception after
abortion and post-partum concluded that in the nurslings of mothers ingesting the
pill no adverse effects in regard to bone growth, genital development and im-
paired fertility later in adulthood can be substantiated, and doubted whether
sex hormones as contained in present pill preparations are transferred via the
breast milk into the system of the nursling in sufficient amounts to cause accelerated
bone maturation or any other adverse effects.
Work in this whole field has been hampered by the difficulties encountered in
developing reliable assay techniques for the study of contraceptive steroids and
their metabolites in milk.
It is difficult to draw any firm conclusions from the very few preliminary
studies which have been published relating to human research in this field, and
which have involved the use of radioactive isotope labelled steroids, of necessity
given to lactating but non-nursing mothers (Laumas, Malkani & Bhatnagar,
1967; Van der Molen, Hart & Wijmenga, 1969; Pincus, Bialy & Layne, 1966;
Wijmenga & Van der Molen, 1969). In three of the studies it was specifically stated
that the study was performed in the immediate post-partum period and lactation
was not established by suckling. Considerable variation occurred in the volumes of
milk obtained by breast pumping but, in general, volumes were low. Conclusions
had to be based upon the percentage of radioactivity recovered from the milk,
but not upon the percentage of biologically active steroid or inactive metabolites.
These percentages varied from 0-0002 to 0-013% in the cases in whom labelled
oestrogens were given and 0-0002 to 1-5% in the cases in whom labelled gestagens
were used. Thus at this stage any thoughts on implications must be purely specu-
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lative, and more work is needed, particularly in view of the trend towards the use
of lower dose and/or different preparations even in non-lactating women.
The difficulties of extrapolating animal findings to the human are well known.
Nonetheless, toxicological studies of which we are aware have shown no evidence
of any effect on the offspring of nursing rhesus monkeys given up to 100 fig
ethinyl oestradiol/kg body weight daily for 12 weeks. Vorherr (1973) in his animal
experiments gave lactating post-partum mother rats oral oestrogen-progestogen
doses comparable on a weight basis to those given in the pill. Neither these doses
nor those up to five-fold the corresponding human oral contraceptive doses led to
impairment of the suckling pups' weight gain, maturation or reproductive func-
tion, or to the development of cancer later in their lives.
Despite the progress in development of reliable techniques of steroid assay,
such are the problems of interpretation that even in the light of present day
knowledge it may take many years of investigation to reach definitive conclusions
with respect to humans.
Towards this end, WHO is planning to support research designed to study the
transfer of commonly used progestogens and oestrogens in oral contraceptive
preparations and progestogens in injectable preparations and to quantify and to
identify the nature of whatever form of these steroids may be transferred, be it
biologically active or inactive, as a first step towards the solution of the second
question.
Return of fertility during lactation
There is sufficient evidence in the literature to show that lactation gives some
measure of protection against conception, but the mechanism whereby this is
achieved remains to be clarified. Although this protection may be substantial
during the phase of lactational amenorrhoea, unacceptably high rates of preg-
nancy (up to 10%) during this phase have been reported, with a marked increase
following the return of menstruation but before weaning (Buchanan, 1975). The
duration of protection can thus only be measured in broad terms and cannot
be predicted with certainty. If a simple technique could be devised which would
enable a nursing mother to determine with some exactitude when she is first at
risk of becoming pregnant this would obviously represent a major advance.
The WHO Task Force (WHO, 1976) primarily concerned with research con-
cerning methods for the determination of the fertile period is accumulating data
from several centres on the correlation between ovulation, as determined by direct
observation and plasma levels of steroids, and gonadotrophins to identify those
parameters which could be used as reference points to judge the reliability of
methods developed for the prediction of the fertile period which are suitable for
home use. Efforts are being made to develop assay kits which would allow women
to predict and to detect the occurrence of ovulation. Radioimmune assays have
been developed for various urinary oestrogen and progesterone metabolites which
could possibly form the basis of such 'do it yourself kits', if continuing research
confirms specific relationships with the occurrence of ovulation. The scientists in
available at https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0021932000023877
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 07:47:48, subject to the Cambridge Core terms of use,
118 R. M.Bernard
this Task Force are in addition developing and using devices from the fields of
medical physics and bioengineering to investigate changes in vaginal tempera-
ture, heat flux, blood volume, colour and secretions and in biopotential associated
with ovulation.
The promoters of fertility regulation based on periodic abstinence believe that
women can be taught through awareness of changes in their cervical mucus, with
or without monitoring changes in basal body temperature, how to recognize the
onset of the fertile period, regardless of their reproductive cyclic status. The Task
Force is currently investigating on a multi-centre basis the use-efficacy of these
methods of fertility regulation in women with normal ovulatory cycles. Should
these methods prove reliable further consideration will be given to the exploration
of their use during lactation as a means whereby the timing of ovulation, and thus
the need for contraceptive measures or abstinence, can be identified.
Discussion
Thomson: How do you propose to ensure the regularity of taking the contraceptives ?
I take it that these people will not just be given packets of the appropriate hormonal
preparation and left to it? There will have to be some kind of supervision of the
regularity of taking them and so on, especially in relatively unsophisticated
communities.
Bernard: The scientists with whom it would be proposed to collaborate are fully
aware of the need to monitor the usage of contraceptives and the importance of
such control. It is proposed that subjects be seen twice before the start of contra-
ceptive therapy at six weeks post-partum when there can be no doubt that lacta-
tion is fully established. Thereafter mother and child would be seen at monthly
intervals for six months at the concerned hospital centre by physicians, and
intermediate visits would be made to the home by a health visitor, to ensure
essential medicare and to check on the regular use of the given contraceptive.
The women would enter the study after careful explanation of its aims and parti-
cularly for the need for regular pill taking.
Robyn: Is any comparison being made between what lactation can achieve, in
terms of contraception, and what can be achieved by the modern methods taking
into consideration their acceptability which may be very low ? Is there any possi-
bility of making such a comparison in your study ?
Bernard: It is not intended to make such a comparison. Since only a limited number
of subjects would be observed, including non-contracepting controls, over a very
limited period of time, efforts to assess contraceptive efficacy would probably not
be meaningful under these circumstances.
Thomson: You talked about a controlled study, then about women electing to take
part. Do you think that the effects of self-selection can be overcome by matching?
A randomized trial would be ideal, but is scarcely feasible.
Bernard: I agree that such a randomized trial would not be feasible. Randomi-
zation only to the use of different contraceptive pills can be achieved but not to
placebo pills which are ineffective contraceptives. The woman must be allowed to
use the method of contraception of her choice. Within such a study as far as
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matching is concerned every effort would be made to eliminate as many variables as
possible.
Mosley: Would it be considered ethically right to take a group of IUD acceptors
who would not object to taking the pill and to ask them to take two or three
cycles of the pill, including a placebo preparation ? This would get around the
problem of controls.
Bernard: Ethical questions always require considerable reflection. If it were
considered ethically right then it may well be that your suggestion would get
around the problem of controls.
Mosley: It would be possible to assign randomly the preparations, including the
placebo.
Thomson: We cannot exclude possibly awkward interaction effects.
Mosley: I agree. But we might wonder whether we should neglect to look for the
effects of an extremely important variable because of the possibility of some
potential interaction effect which is unknown.
Thomson: In effect, 'Let not the best be the enemy of the good'.
Gray: The objective of the study is purely comparative. About the controls, and
the different study strategies that can be adopted, each woman will be her own
internal control, insofar as changes over time are being measured. There would be
ethical problems with the use of a placebo, but I doubt that placebo effects would
be sufficient to alter the findings. If there are pure placebo effects related, say, to
the use of the pill, these should be seen in the oestrogen-containing group as well
as in the progestogen only group. I do not think a cross-over design would be
practicable, because of the changes in lactation over time which would make such
a design extremely complex.
Tyson: Will there be any limits on the number of times that the woman breast-
feeds her child during the study?
Gray: No—the objective is to try, as far as possible, to eliminate the effects of
mother-child interaction. If there is an effect of the steroids, it is presumably an
effect on the capacity of the breast to produce milk. We will do breast pumping
alone, as the only standardized means of assessment. This is not an adequate
assessment of total milk output, but it will be used as a device to obtain comparison
between drugs because it seems to be the easiest procedure to standardize.
Liebrich: Oestrogens would probably affect the fat content of the milk in some way.
This is the main source of calories for the baby. The nutritional value of the milk
cannot be assessed unless there is some assessment of its quality, perhaps from the
rate of weight gain of the baby, to ensure that the right amount of fat is produced
and secreted.
Bernard: The weight gain of the infants would be closely observed. The quality of
the milk samples would be studied in respect of many constituents, including the
free fatty acids and the long-chain fatty acids.
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